Equidad en salud en las pruebas de biomarcadores y terapias dirigidas
La terapia dirigida puede mejorar la supervivencia y la calidad de vida al conectar a los pacientes con el tratamiento más beneficioso para su enfermedad.
Cancer Patients and Survivors Overwhelmingly Agree Biomarker Testing Improved Their Treatment
October 19, 2023
Overview
The American Cancer Society Cancer Action Network (ACS CAN) empowers advocates across the country to make their voices heard and influence evidence-based public policy change, as well as legislative and regulatory solutions that will reduce the cancer burden. As part of this effort, ACS CAN deploys surveys to better understand cancer patient and survivor experiences and perspectives, through our Survivor Views research panel. The panel is a group of cancer patients and survivors who respond to regular surveys and provide important insights to support ACS CAN’s advocacy work at all levels of government.
Fielded September 12-25, 2023, our latest survey explores experiences with biomarker testing. The web-based survey was conducted among 1,222n cancer patients and survivors nationwide who have been diagnosed with or treated for cancer in the last seven years.
Summary of Findings
Higher Income and Education Groups are Most Likely to Report Having and Asking for Biomarker Testing
About half (49%) of those surveyed have had biomarker testing for their cancer, while 29% say they have not and 22% are unsure. This is an increase from 39% in 2020 who had biomarker testing. Those most likely to have had biomarker testing include younger patients, those with higher incomes, and those with higher educational attainment. Among those who have had biomarker testing, 84% say their provider initiated the process and 14% report asking for the test. Those with college- or post-graduate degrees more frequently report initiating the conversation about biomarker testing with their provider, and patients and survivors with annual household income above $125,000 are twice as likely to report asking their provider about biomarker testing as those in the $50,000-$75,000 annual household income bracket.
Biomarker testing was covered by insurance for 76% of those who had the test and half had no out of pocket costs. Those enrolled in Medicare, Medicaid, or an employer plan are more likely to report coverage for biomarker testing than those using a plan purchased privately such as through the marketplace. Nine percent of those who did not have biomarker testing say it was because of cost or coverage concerns. This is a significant improvement since the last time this question was asked in 2020, when 29% mentioned cost and coverage as reasons they did not have biomarker testing.
Cancer Patients and Survivors Overwhelmingly Agree Biomarker Testing Improved Their Treatment
Over three-quarters (77%) of those who have had biomarker testing agree that it gave their providers valuable information that improved their ability to treat the patient’s cancer. Fifty-three percent say they are more likely to recover because of the biomarker testing. Half say they were able to avoid unnecessary treatments or procedures because they had biomarker testing. The results of biomarker testing led to changes in treatment protocol for 23%, and allowed 3% to find and enroll in a clinical trial.
Cancer patients and survivors who have had biomarker testing describe many specific ways their experience benefitted from the testing, particularly when it comes to having the peace of mind that the best treatment plan was followed as a result. Some representative quotes from patients and survivors follow:
Q: How might your experience have been different if you hadn’t had biomarker testing?
“I was given 6 months to a year to live. The biomarkers led me to an immunotherapy trial that saved my life.”
“Biomarker testing entered me into a treatment plan that has given me a complete response after failure of two prior plans.”
“We would be less certain about the optimal treatment plan, based on clinical knowledge and standards in place today.”
Many of those who did not have biomarker testing (35%) simply weren’t a good candidate for it, but 69% never discussed it with a provider. Seventy-seven percent of those who did not have biomarker testing agree they would want it done if they were a good candidate for it.
Methodology
ACS CAN’s Survivor Views research initiative was designed to support the organization’s efforts to end suffering and death from cancer through public policy advocacy. Data provided by cancer patients and survivors as part of this project allows for a greater understanding of their experiences and opinions on cancer-related issues and gives voice to cancer patients and survivors in the shaping and advocating of public policies that help prevent, detect, and treat cancer and promote a more positive quality of life for those impacted.
To ensure the protection of all participants in this initiative all research protocols, questionnaires, and communications are reviewed by the Morehouse School of Medicine Institutional Review Board.
The survey population is comprised of individuals who meet the following criteria:
- Diagnosed with and/or treated for cancer within the last seven years
- Over the age of 18 (parents of childhood cancer survivors were invited to participate on behalf of their minor children)
- Reside in the US or US territories
Potential Survivor Views participants were invited to participate through email invitations, social media promotion, and partner group outreach. Those who agreed to participate after reviewing the informed consent information completed a brief survey including demographic and cancer history information to inform analysis as well as topical questions as discussed in this document. The data were collected between September 12-25, 2023. A total of 1,222 cohort participants responded to the survey. Differences reported between groups are tested for statistical significance at a 95% confidence interval.
About ACS CAN
The American Cancer Society Cancer Action Network (ACS CAN) advocates for evidence-based public policies to reduce the cancer burden for everyone. We engage our volunteers across the country to make their voices heard by policymakers at every level of government. We believe everyone should have a fair and just opportunity to prevent, detect, treat, and survive cancer. Since 2001, as the American Cancer Society’s nonprofit, nonpartisan advocacy affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality affordable health care, and advanced proven tobacco control measures. We stand with our volunteers, working to make cancer a top priority for policymakers in cities, states and our nation’s capital. Join the fight by visiting www.fightcancer.org.